BMC Cancer is calling for submissions to our Collection on Genitourinary cancers: Advances in research, diagnosis, and treatment.

Genitourinary cancers, spanning a wide range of malignancies affecting both the urinary and reproductive systems, represent a significant global health challenge. These malignancies affect millions of individuals worldwide and are associated with substantial morbidity and mortality. Recent advancements in understanding the molecular and genetic underpinnings of these cancers have paved the way for innovative diagnostic and therapeutic approaches. As researchers continue to explore the complexities of genitourinary tumors, a clearer picture of their pathophysiology is emerging, which is crucial for developing targeted treatment strategies.

The ongoing research in genitourinary cancers is pivotal for improving patient outcomes. With the advent of precision medicine, immunotherapy, and novel biomarker identification, there have been significant strides in tailoring treatments to individual patients. For instance, the incorporation of genomic profiling in clinical practice has revolutionized our approach to managing prostate cancer, enabling more effective and personalized therapies. Furthermore, ongoing clinical trials are continually expanding our knowledge base, ultimately aiming to enhance survival rates and quality of life for patients diagnosed with these cancers.

Continued research in this field holds the promise of further breakthroughs in diagnostics and treatment modalities. As our understanding of the molecular drivers of genitourinary cancers deepens, we may witness the development of innovative therapeutic agents, enhanced screening methods, and more effective strategies for early detection. Future research could also lead to better integration of multidisciplinary approaches, offering hope for improved management and outcomes for patients facing these challenging diseases.

This Collection welcomes research articles on topics including, but not limited to:

- Genetic mutations and molecular pathways in genitourinary cancers

- Advances in biomarker discovery for early detection

- Imaging technology for early detection

- Liquid biopsy

-Genomic testing for personalized treatment plans

- Immuno-oncology combinations and novel drug classes

- Role of surgery and minimally invasive procedures

- Targeted therapies for specific genitourinary malignancies

- Overcoming resistance to chemotherapy and targeted therapies

- New clinical trials and cutting-edge research

- Translational research bridging laboratory findings to clinical applications

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

BMC Cancer welcomes submissions to the "Cancer evolution: from premalignancy to tumor progression" Collection that explore the intricate processes underlying cancer development. Understanding the progression of cancer from premalignant states to fully developed tumors is essential for developing effective therapeutic strategies. Cancer evolution encompasses a range of biological processes, including genetic mutations, epigenetic changes, and microenvironmental influences. Investigating these mechanisms offers insights into the complex pathways that lead to malignancy. Recent advances in genomic sequencing and single-cell analysis have illuminated the heterogeneity of tumors and their precursors, revealing the intricate dynamics that govern cancer evolution and progression. By unraveling these processes, researchers can identify potential biomarkers and therapeutic targets to improve patient outcomes.

The significance of this research lies in its potential to revolutionize cancer prevention and treatment. As we better understand the early stages of cancer development, we can implement more effective screening strategies and interventions aimed at halting progression before malignancy occurs. Advances in precision medicine have already paved the way for personalized therapies that target specific mutations. Continued exploration into the molecular and cellular foundations of cancer evolution is crucial for enhancing our ability to manage and treat this complex disease.

If this research trajectory continues, we can anticipate significant advancements in the field of oncology. Future studies may lead to the identification of novel biomarkers that predict cancer progression, as well as the development of targeted therapies aimed at early-stage cancers. The integration of artificial intelligence and machine learning in cancer research could further accelerate our understanding of tumor evolution and foster the creation of innovative treatment strategies that are tailored to individual patients.

Topics welcome to this Collection include, but are not limited to, the following:

- Mechanisms of tumor heterogeneity

- Computational modeling of cancer evolution

- Cancer ecology

- Biomarkers for early cancer detection

- The role of the tumor microenvironment

- Epigenetic and genetic alterations in cancer progression

- Precision medicine approaches in oncology

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.